Barley/CHD claim
This article was originally published in The Tan Sheet
Executive Summary
Whole barley and dry milled barley products may bear a health claim linking soluble dietary fiber to a reduced risk of coronary heart disease, FDA announces in an interim final rule published in the Federal Register Dec. 23. The addition of barley marks the third amendment to a 1997 health claim linking 3g or more of beta-glucan soluble fiber per day from oat bran, rolled oats or whole oat flour to a reduction in risk of CHD. Soluble fiber from psyllium seed husk was added in 1998 and oatrim was deemed an eligible source of beta-glucan soluble fiber in 2002 ("The Tan Sheet" Oct. 7, 2002, In Brief). The National Barley Foods Council petitioned FDA for the amendment in August 2004...
You may also be interested in...
CHD/barley
Separately, the agency announced in the FR that it is adopting as a final rule a January amendment to the CHD/dietary fiber health claim, which named barley as an additional source of beta-glucan soluble fiber (1"The Tan Sheet" Jan. 2, 2006, In Brief)...
Oatrim health claim
Soluble fiber/coronary heart disease health claim expanded to include oatrim as an eligible source of whole oat beta-glucan soluble fiber, FDA says in 1interim final rule published Oct. 2. Agency describes oatrim as "the soluble fraction of alpha-amylase hydrolyzed oat bran or whole oat flour with a beta-glucan soluble fiber content of up to 10% on a dry weight basis (dwb) and not less than that of the starting material (dwb)." Action comes in response to citizen petition by joint venture Quaker/Rhodia to expand health claim to include Betatrim, the brand name for a group of beta-glucan-containing food ingredients (2"The Tan Sheet" July 30, 2001, In Brief). However, agency declines to limit health claim to only Betatrim products; instead it will be available "to any substances that meet FDA's definition of oatrim"...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.